

#FutureFresenius – Advancing Patient Care

Company Presentation, March 2023

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts.

Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.



1 Company Overview

- 2 Strategic Update
- 3 Business update FY/22
- 4 Financial priorities & Outlook FY/23
- 5 Attachments


Fresenius is at the heart of healthcare



A Global Leader in Healthcare Products and Services




Global Trends offer Growth Opportunities for Fresenius




Sources: ¹ UN, Ageing and health (2021) ² UBS, Longer Term Investments: EM healthcare (2018) ³ IDF Diabetes Atlas (2021) ⁴ AAM report (2021) ⁵ UBS, Longer Term Investments: Generics (2018)

Fresenius Group: Global Revenue Base in Growing, Non-Cyclical Markets



Before special items 2018 excluding IFRS 16

Fresenius Group: Track Record of Healthy Organic Revenue Growth



FRESENIUS

#FutureFresenius

Advancing Patient Care

Operating Companies

Profitability optimization and growth

Investment Companies

Financial value management



Fresenius Group: Our Healthcare Portfolio

Operating Companies

Investment Companies

FRESENIUS KABI



Ownership: 100%

Health products for critically and chronically ill patients

- Biopharmaceuticals
- Clinical Nutrition
- MedTech: Infusion and Nutrition Systems / Transfusion and Cell Technologies
- IV Drugs & Solutions

Sales 2022: €7.9 bn

FRESENIUS HELIOS



Ownership: 100%

Health services along the care continuum

- Acute care
- Outpatient services
- Occupational risk prevention
- Fertility services

Sales 2022: €11.7 bn

FRESENIUS MEDICAL CARE



Ownership: ~32%

Dialysis services and products

- Dialysis services
- Products for hemodialysis and peritoneal dialysis
- Critical care solutions
- Complementary assets to establish holistic treatment approach

Sales 2022: €19.4 bn





Ownership: 77%

Project business and services

- Post-acute care
- Project development and planning, turnkey construction
- Maintenance, technical and total operational management

Sales 2022: €2.4 bn

Fresenius Kabi: Comprehensive product portfolio for critically and chronically ill patients

- Balanced market reach with leading positions
- Vision 2026: "3+1" strategy
 - Strong focus on key growth vectors Nutrition, Biopharma and MedTech
 - Strengthening resilience of volume businesses
- Increasing global competitiveness and organizational effectiveness

Biopharmaceuticals


Clinical nutrition

Medical devices /

Generic IV drugs

IV Fluids

transfusion technology



F FRESENIUS

B

G

Fresenius Helios: Health services along the care continuum

- Market leader in size and quality driving for capital efficiency and value accretive growth
- ~6%¹ share in German acute care hospital market and ~12%¹ share in Spanish private hospital market
- Quality is key: defined quality targets, publication of medical treatment results, peer review processes
- Development of new business models to foster digitalization and benefit from trend towards outpatient treatments

Acute care



Outpatient

		$\mathbf{\mathbf{y}}$			

Occupational risk prevention

Fertility services

¹ Based on sales



Fresenius Medical Care: Dialysis services and products

- The world's leading provider of dialysis products and services treating ~345,000 patients¹ in >4,100 clinics¹
- Provide care and products of highest quality
- Leveraging core competencies to address global healthcare challenges and further expand in the Renal Care Continuum and beyond
- Advancing global transformation program FME25 to enable further sustainable profitable growth and execution on strategy

Dialysis services

Dialysis products

Critical care solutions

Complementary assets

Sales by Region



Sales by Products and Services



Market Dynamics

Increase in global demand

>1.6 million p.a.

patients worldwide will need continuous renal replacement therapy to treat acute kidney failure in 2030

Home dialysis

By 2025, the Company aims to perform **25%** of all treatments in the U.S. in a home setting

Digitalization is driving new treatment models

Leverage ever larger data sets from **~53 million** dialysis treatments per year (2021) to further improve and personalize treatments

¹ As of December 31, 2022



භිළු

+

Fresenius Vamed: Project business and services

- Manages hospital construction/expansion projects and provides services for healthcare facilities worldwide
- Offers project development, planning, turnkey construction, maintenance as well as technical management, and total operational management
- Strong track record: More than 1,000 projects in 98 countries completed

Services

Projects

Post-acute care

 Leading post-acute care provider in central Europe



Market Dynamics Telemedicine market in Europe is estimated to grow

from 2020 to 2026.

Global preventive healthcare is estimated to grow

9.5% p.a.

till 2025.

Outsourcing of non-medical services provided by public institutions to private providers grew in Germany by


from 2014 to 2019.

Emerging markets' share of global health expenditure will grow to


33% by 2022.

47


Progressive dividend policy - dividend proposal of €0.92 per share



Fresenius SE: Fresenius Share & Shareholder Structure



Analyst recommendations



As of December 31, 2022



1 Company Overview

² Strategic Update

- 3 Business update FY/22
- 4 Financial priorities & Outlook FY/23
- 5 Attachments

RESET under way – strategic review completed



2022 numbers delivered, 2023 outlook tough but realistic



Action on simpler, value-oriented structure



New management team built



More rigorous financial framework



Picking up the pace on costs out and portfolio changes

Momentum towards #FutureFresenius

Structural Fresenius Medical Care to be deconsolidated simplification Focus on Fresenius Kabi and Fresenius Helios Sharpen Active portfolio management for assets focus **Ambitious EBIT margin bands** Accelerate performance ~1bn annual structural productivity improvement by 2025

Becoming an industry-leading, therapy-focused healthcare company – Advancing patient care

FSE / FMC to focus on performance



Supportive and active long-term shareholder to benefit from FMC value creation plan

Change from full consolidation to **at-equity consolidation of FMC** after conversion

No relevant impact on material financing arrangements at both FSE and FMC

FSE one-time costs in low double-digit €m range; negligible dissynergies from deconsolidation

Value upside retained, strategic optionality created

Implementation expected Q3-4 2023

Clear benefits for FSE and FMC

F FRESENIUS



>

>

Reduced complexity, increased transparency

Sharpened management focus on operating companies

Enhanced strategic flexibility and **optionality**





Simplified, entrepreneurial governance structure

Freed up management capacity to execute on turnaround



<

Focused and faster decision-making



 $\langle \rangle$

Additional **flexibility on** FMC's capital allocation

#FutureFresenius


Advancing Patient Care

Operating Companies

Profitability optimization and growth

Investment Companies

Financial value management



Sharpen focus – Drive transformative growth with "3+1 strategy" at Kabi

Selective market positions



- Strong focus on key growth vectors
- Strengthening resilience of volume businesses
- Increased transparency and targeted segmentation
- Further details during May 2023 CMD

FY 22 Net Sales Arket growth outlook

Highly specialized healthcare products, with balanced market reach

Nutrition

- **#1** Global Parenteral Nutrition
- #2 Enteral Nutrition Europe & LATAM

Margin-accretive business

Drive global roll-out via product innovation and geographic expansion

MedTech

€1.5B

- **#1** Global Blood Collection
- **#2** Stationary Infusion System Europe & LATAM

Innovative Ivenix platform to penetrate US infusion market and to enhance interoperability and clinical functions

Biopharma

End-to-end Biopharma business with state-of-theart biologic manufacturing

Strong organic growth with expansion of product portfolio and entry into US market in 2023

IV Drugs & Solutions

€3.9B

€0.2B

#1 global hospital-sold Injectable Gx

Highly cash-accretive business

Strengthening **resilience** with **quality** and strong **cost focus**

Sharpen focus – Drive capital efficiency and value accretive growth at Helios



- Continuing stable margin delivery
- Increased focus on return on capital and cash flow generation
- Clear strategy for value creation across portfolio
- CMD envisaged for 1Q2024


Leading healthcare services delivering value for >24 million patients yearly



#1 private hospital provider in Germany and Spain
State-of-the-art medical quality and patient satisfaction
Strong track record of cutting-edge technology and innovation
Shaping industry trends in digitalization and outpatient care
Leading fertility platform with strong brands and expansion potential

🔮 FY 22 Net Sales 🛛 🔊 Market growth outlook

Sharpen focus – Exit businesses in less attractive markets or where FSE not best owner





Develop business cells with **strong organic growth paths**



Strengthen portfolio focus and capital allocation



Exit **~5+ cells with triple-digit-million** € sales each, where FSE is not the best owner



Support deleveraging

Details on portfolio exits over next 12-18 months

New, more rigorous F³ – Fresenius Financial Framework



 $^{\rm 1}$ Cash Conversion Rate – defined as adjusted FCFbIT / EBIT before special items All figures before special items

A clearer picture for 2024 and beyond




#FutureFresenius – Maximum patient impact across platforms for leading therapies

Refocus on patient impact as a **trusted partner in world-class therapies**


Drive high-quality, value-generating innovation

Advance leadership in system-critical products and services



#FutureFresenius – Our near-term agenda





30




- 1 Company Overview
- 2 Strategic Update RESET under way

3 Business update FY/22


- 4 Financial priorities & Outlook FY/23
- 5 Attachments

FY/22 – Delivered revised guidance



All growth rates in constant currency (cc) Before special items Net income attributable to shareholders of Fresenius SE & Co. KGaA ¹ excluding acquisitions of Ivenix and mAbxience

Q4/22 – Solid quarter against the backdrop of challenging macro environment



All P&L growth rates in constant currency (cc) Before special items; Net income growth excluding Ivenix and mAbxience acquisitions Net income attributable to shareholders of Fresenius SE & Co. KGaA ¹ excluding acquisitions of Ivenix and mAbxience

Strong operating cash flow in Q4/22


€m	Q4/22	Q4/21	FY/22	FY/21
OCF	1,824	1,749	4,198	5,078
% OCF Margin	17.1%	17.5%	10.3%	13.5%
Сарех	-605	-674	-1,777	-2,017
Capex in % of revenue	5.6%	6.7%	4.4%	5.3%
Acquisitions	-39	-157	-830	-800
Dividends	-73	-77	-890	-1,068
FCF	1,107	841	701	1,193

- Strong Q4/22 operating cash flow
- Good cash collections and improved working capital management in particular at Fresenius Helios
- Prudent CAPEX spend in FY/22 resulting in strong Free Cash Flow
- FY/22 FCF impacted by strategic M&A

Fresenius Kabi with strong organic revenue growth Q4/22 results



QUARTERLY FINANCIALS



MAIN DEVELOPMENTS


- Strong organic revenue growth in
 all three growth vectors
 supplemented by healthy growth in
 the volume business
- Biopharmaceuticals with continued strong growth trajectory
- EBIT margin¹ was impacted by non-cash one-time write offs, primarily related to a capitalized in-process R&D project in North America

Before special items,

¹ Q2/22, Q3/22, Q4/22 margin and EBIT cc growth excluding Ivenix and mAbxience acquisitions

3+1 strategy: Adding to our growth opportunities





Fresenius Helios delivers good close to the year Q4/22 results



QUARTERLY FINANCIALS 3,500 11.8% 11.7% 7.8% **EBIT Margin** 10.4% 10.4% 3,000 Revenue €m 3,031 2,500 2,882 2,000 Q4/21 Q1/22 Q2/22 Q3/22 Q4/22 **Revenue** 5% 8% 5% 6% 5% growth org. EBTT 3% 15% 1% -1% 5% growth cc


MAIN DEVELOPMENTS

- Healthy organic revenue growth, strong EBIT development
- Helios Germany: Gradually moving to pre-COVID patient structure
- Helios Spain: Very strong and consistent patient demand in Spain and Latin America
- Helios Fertility: Macroeconomic uncertainty and associated changed customer behavior resulting in a delay of treatment starts

Before special items

Fresenius Vamed with weak quarter marked by one-time effects Q4/22 results





MAIN DEVELOPMENTS

- Service business showing solid topline performance, but one-time items and macro headwinds impact profitability
- Weak top-line performance driven by difficult economic environment and negative one-time items adversely impact earnings in **project business**
- Adverse macro environment leading to negative one-time effects due to reassessment and revaluation of claims and legal proceedings as well as certain business initiations that did not materialize as planned




- 1 Company Overview
- 2 Strategic Update RESET under way
- 3 Business update FY/22


4 Financial priorities & Outlook

5 Attachments


Clear financial priorities to accelerate performance and deliver value to shareholders



Defining our financial ambition levels



1 Increase focus and transparency on our path to **#FutureFresenius**



2 Driving structural productivity with more ambitious cost savings program

across the FSE Group... ... exceeding 2022 goals... ... updating 2025 targets Cost savings -Cost savings -Net income to **Cost reduction**, e.g. ~€1,000m Net income **EBIT** view New FBIT view (>**Procurement** EBIT savings **Processes** ~€450m achieved ~€650m - €500m Net income SG&A savings achieved ~€250m €289m Divest non-core assets, e.g. €300m €131m €150m €152m ~€350m **Targeted divestments** ~€200m €158m Selective country operation exits 2023 2023E 2025E 2022A 2022A Target Thereof FME


New target setting based on EBIT to reflect profitability focus

One-off costs at around ~€700-€750m (thereof €250-300m excl. FMC) between 2023 and 2025, of which ~2/3 expected to occur in 2023

F FRESENIUS

Targeted programs

3Focus on improving capital efficiency and returns



1 At LTM average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures; before special items

FY/23 – A year of structural progression

Persistent headwinds...



Reduced government support (*excl. energy*)

Increased interest rates

... but structural progression

Ramp-up of cost savings

FMC deconsolidation

((())))

Further portfolio measures

Uptake of growth vectors

Increase to PY

Fresenius Group

Revenue growth (organic) Low-to-mid-single-digit growth

EBIT (cc growth)¹ including FMC: Broadly flat-to-high-single digit decline EBIT (cc growth) excluding FMC: Broadly flat-to-mid-single digit decline

Operating Companies


structural EBIT margin band of 9 – 11%

Investment Companies

- Low-to-mid-single-digit Low-to-mid-single-digit organic revenue growth revenue growth in cc **FRESENIUS FRESENIUS** MEDICAL CARE Around 1pp below Flat-to-high-single-digit operating income decline excl 2022 PRF¹ structural EBIT margin band of 14 – 17% • Mid-single-digit Low-to-mid-single-digit organic revenue growth organic revenue growth RESENIUS FRESENIUS VAMED Within
 - Clearly below structural EBIT margin band of 4 – 6%


1 Adjusted EBIT excluding Provider Relief Funding (PRF); In 2022 Fresenius Medical Care received €277m (at current currency) Provider Relief Funding; No Provider Relief Funding support expected for 2023

FY/23 – Other financial KPIs



2023 Targets for Environment, Social, Governance (ESG) KPIs

Targets aligned with Management Board Compensation Short-term Incentive (STI) 2023






Attachments

Structural simplification – New structure expected to become effective in Q3 or Q4 2023



Key aspects & next steps

- Conversion into AG based on resolution of FMC extraordinary shareholder meeting
- 75% of FMC share capital present at EGM required to approve resolution
- Deconsolidation effective with registration of conversion into commercial register
- Implementation likely to take ~4 6 months post EGM



AGM = Annual general meeting EGM = Extraordinary general meeting

Fresenius Kabi: Q4 & FY/22 Organic Revenue Growth by Regions

€m	Q4/22	Δ YoY organic	FY/22	Δ YoY organic
North America	669	3%	2,522	0%
Europe	724	6%	2,691	5%
Emerging Markets	643	11%	2,637	4%
Total revenue	2,036	7%	7,850	3%

Fresenius Kabi: Q4 & FY/22 Organic Revenue Growth by Product Segment

€m	Q4/22	Δ YoY organic	FY/22	Δ YoY organic
IV Drugs	752	2%	2,879	-3%
Infusion Therapy	267	12%	1,002	13%
Clinical Nutrition	544	6%	2,280	4%
Medical Devices/ Transfusion Technology	401	8%	1,501	3%
Biopharmaceuticals	72	71%	188	108%
Total revenue	2,036	7%	7,850	3%

Fresenius Kabi: Q4 & FY/22 EBIT Growth

€m	Q4/22	∆ YoY cc	FY/22	Δ YoY cc
North America	145	-4%	661	-7%
Margin	21.7%	-140 bps	26.2%	-200 bps
Europe	114	77%	340	-10%
Margin	15.7%	+610 bps	12.6%	-210 bps
Emerging Markets	104	-49%	597	-14%
Margin	16.2%	-1870 bps	22.6%	-440 bps
Corporate and Corporate R&D	-127	1%	-518	4%
Total EBIT	236	-13% ¹	1,080	-10% ¹
Margin	11.6%	-370 bps	13.8%	-220 bps

All figures before special items Margin growth at actual rates ¹ Excluding Ivenix and mAbxience acquisitions

For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.

Fresenius Helios: Q4 & FY/22 Key Financials

€m	Q4/22	Δ YoY cc	FY/22	∆ YoY cc
Total revenue	3,031	5% ¹	11,716	6% ¹
Thereof Helios Germany	1,749	0%1	7,021	4%1
Thereof Helios Spain	1,214	12% ¹	4,441	9%1
Thereof Helios Fertility	66	1%1	250	1%1
Total EBIT Margin	354 11.7%	5% -10 bps	1,185 10.1%	5% -20 bps
Thereof Helios Germany Margin	174 9.9%	2% +10 bps	623 8.9%	2% -20 bps
Thereof Helios Spain Margin	172 14.2%	7% -70 bps	556 12.5%	8% -30 bps
Thereof Helios Fertility Margin	6 9.1%	0% -70 bps	21 8.4%	0% -590 bps
Thereof Corporate	2		-15	

¹ Organic growth

All figures before special items

For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.

Fresenius Helios: Key Metrics

	FY/22	FY/21	Δ
Helios Germany			
Hospitals - Acute care hospitals	87 84	90 87	-3% -3%
Beds - Acute care hospitals	30,352 29,786	30,487 29,955	0% -1%
Admissions - patients treated in hospital - patients treated as outpatient	5,508,158 1,079,776 4,423,482	5,444,546 1,048,946 4,390,553	
Helios Spain (incl. Latin America)			
Hospitals	58	56	4%
Beds	8,259	8,174	1%
Admissions (including outpatients) - patients treated in hospital - patients treated as outpatient	18,853,264 1,067,410 17,785,854	17,122,592 982,204 16,140,388	

Fresenius Vamed: Q4 & FY/22 Key Financials

€m	Q4/22	Δ YoY cc	FY/22	Δ YoY cc
Total revenue Thereof organic revenue	712	-5% -5%	2,359	2% 2%
Project business	267	-20%	674	-6%
Service business	445	7%	1,685	6%
Total EBIT	-9	-114%	20	-81%
Order intake ¹	572		1,241	
Order backlog ¹			3,689	6%²

¹ Project business only ² Versus December 31, 2021

Fresenius Group: Calculation of Noncontrolling Interests

€m	FY/22	FY/21
Earnings before tax and noncontrolling interests	3,471	3,748
Taxes	-824	-848
Noncontrolling interests, thereof	-918	-1,033
Fresenius Medical Care net income not attributable to Fresenius (FY/22: ~68%)	-621	-690
Noncontrolling interest holders in Fresenius Medical Care	-222	-250
Noncontrolling interest holders in Fresenius Kabi (- \in 56 m), Fresenius Helios (- \in 17 m), Fresenius Vamed (- \in 6 m) and due to Fresenius Vamed's 23% external ownership (+ \in 4 m)	-75	-93
Net income attributable to Fresenius SE & Co. KGaA	1,729	1,867

Before special items

For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.

Fresenius Group: Cash Flow

€m	Q4/22	LTM Margin	Δ ΥοΥ
Operating Cash Flow	1,824	10.3%	4%
Capex (net)	-605	-4.4%	10%
Free Cash Flow	1,219	5.9%	13%
(before acquisitions and dividends)			
Acquisitions (net)	-39		
Dividends	-73		
Free Cash Flow (after acquisitions and dividends)	1,107	1.7%	32%

Fresenius Group: Reconciliation adjusted Free Cash Flow for CCR

€m	Q4/22	FY/22
Operating Cash Flow	1,824	4,198
Capex (net)	-605	-1,777
Free Cash Flow	1,219	2,421
(before acquisitions and dividends)		
Special items		
(net income before minorities)	+274	+530
Interests	+157	+533
(before special items)		
Taxes	+218	+824
(before special items)	. 210	. 52 1
Adjusted Free Cash Flow for CCR	1,868	4,308

Cash Flow development Q4/22

	Operating C	ash Flow	Capex	Capex (net)		sh Flow ¹
m —	Q4/22	Margin	Q4/22	Margin	Q4/22	Margin
FRESENIUS MEDICAL CARE	599	12.0%	-201	-3.6%	398	7.6%
FRESENIUS KABI	298	14.6%	-196	-9.6%	102	5.0%
FRESENIUS HELIOS	956	31.5%	-227	-7.4%	729	24.1%
FRESENIUS VAMED	12	1.7%	47	+6.6%	59	8.3%
Corporate/Other	-41	n.a.	-28	n.a.	-69	n.a.
FRESENIUS Excl. FMC ²	1,225	21.6%	-404	-7.1%	821	14.5%
F FRESENIUS	1,824	17.1%	-605	-5.6%	1,219	11.5%

¹ Before acquisitions and dividends ² Including FMC dividends

Cash Flow development FY/22

	Operating Ca	ash Flow	Capex (net) Free Cash Flo			h Flow ¹
m —	FY/22	Margin	FY/22	Margin	FY/22	Margin
FRESENIUS MEDICAL CARE	2,167	11.2%	-687	-3.6%	1,480	7.6%
FRESENIUS KABI	841	10.7%	-518	-6.6%	323	4.1%
FRESENIUS HELIOS	1,367	11.7%	-554	-4.8%	813	6.9%
FRESENIUS VAMED	-44	-1.9%	19	+0.8%	-25	-1.1%
Corporate/Other	-133	n.a.	-37	n.a.	-170	n.a.
FRESENIUS Excl. FMC ²	2,158	10.0%	-1,090	-5.0%	1,068	5.0%
F FRESENIUS	4,198	10.3%	-1,777	-4.4%	2,421	5.9%

¹ Before acquisitions and dividends ² Including FMC dividends

Estimated COVID-19 Effects Q4 & FY/22

	as repor	Growth ccEstimatedEstimatedas reportedCOVID-19 impact ccgrowth ccincl. COVID-19excl. COVID-19			h cc	
	Q4/22	Q4/21	Q4/22	Q4/21	Q4/22	Q4/21
Revenue	4%	5%	0% to -1%	0% to -1%	4% to 5%	5% to 6%
Net income ¹	-19%	3%	0% to -4%	0% to -4%	-19% to -15%	3% to 7%

	Growth cc as reported incl. COVID-19		Estim COVID-19		Estimated growth cc excl. COVID-19		
	FY/22	FY/21	FY/22	FY/21	FY/22	FY/21	
Revenue	4%	5%	0% to -1%	0% to -1%	4% to 5%	5% to 6%	
Net income ¹	-12%	5%	4% to 0%	-1% to -5%	-16% to -12%	6% to 10%	

¹ Net income attributable to shareholders of Fresenius SE & Co. KGaA; before special items

Revenue by Business Segment – FX, Acquisitions/Divestitures Effects Q4/22

€m	Q4/22	Q4/21	Growth at actual rates	Currency translation effects	Growth at constant rates	Organic growth	Acquisi- tions	Divesti- tures/ Others
Fresenius Medical Care	4,997	4,647	8%	6%	2%	2%	0%	0%
Fresenius Kabi	2,036	1,823	12%	4%	8%	7%	2%	-1%
Fresenius Helios	3,031	2,882	5%	0%	5%	5%	1%	-1%
Fresenius Vamed	712	748	-5%	0%	-5%	-5%	1%	-1%
Total	10,643	9,966	7%	3%	4%	3%	1%	0%

63

Revenue by Business Segment – FX, Acquisitions/Divestitures Effects FY/22

€m	FY/22	FY/21	Growth at actual rates	Currency translation effects	Growth at constant rates	Organic growth	Acquisi- tions	Divesti- tures/ Others
Fresenius Medical Care	19,398	17,619	10%	8%	2%	2%	1%	-1%
Fresenius Kabi	7,850	7,193	9%	5%	4%	3%	1%	0%
Fresenius Helios	11,716	10,891	8%	1%	7%	6%	2%	-1%
Fresenius Vamed	2,359	2,297	3%	1%	2%	2%	1%	-1%
Total	40,840	37,520	9%	5%	4%	3%	1%	0%

64

Financial Calendar / Contact

Financial Calendar		Social Media		
09 May 2023 Results Q1/23		Follow Fresenius Investor Relations & Sustainability on		
17 May 2023	Annual General Meeting	LinkedIn:		
02 August 2023	Results Q2/23	FE125095/2.FE1		
02 November 2023	Results Q3/23			

Please note that these dates could be subject to change.



Contact

Investor Relations & Sustainability Fresenius SE & Co. KGaA phone: +49 6172 608-2485 e-mail: ir-fre@fresenius.com For further information and current news: www.fresenius.com



in

www.twitter.com/fresenius_ir

www.linkedin.com/company/fresenius-investor-relations



#FutureFresenius